Holen Sie sich die Stockscreener-App
13.50
0.37%
0.05
Handel nachbörslich:
13.50
Mineralys Therapeutics Inc Aktie (MLYS) Neueste Nachrichten
Mineralys Therapeutics to Announce Third Quarter 2024 - GlobeNewswire
Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024 - Marketscreener.com
Objective long/short (MLYS) Report - Stock Traders Daily
Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Pivotal Hypertension Trial - MSN
Mineralys Therapeutics (NASDAQ:MLYS) Receives "Buy" Rating from HC Wainwright - MarketBeat
Mineralys Therapeutics : Corporate Overview October 2024 - Marketscreener.com
Mineralys Therapeutics Advances Lorundrostat Trial Progress - TipRanks
Mineralys Therapeutics Completes Enrollment Ahead of - GlobeNewswire
Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension - The Manila Times
Positive Trial Data on Symplicity RDN System Likely to Support MDT Stock - MSN
Mineralys Therapeutics to Host Virtual Event on Hypertension Treatment Advances - MyChesCo
When the Price of (MLYS) Talks, People Listen - Stock Traders Daily
Mineralys to Host Virtual KOL Event on the Unmet Medical Need in Uncontrolled and Resistant Hypertension, and Lorundrostat as a Potential Treatment on October 30, 2024 - The Manila Times
Mineralys to Host Virtual KOL Event on the Unmet Medical - GlobeNewswire
We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate - Yahoo Finance
Hypertension Clinical Trials 2024: FDA Approvals, Medication, - openPR
Hypertension Clinical Trials 2024: FDA Approvals, Medication, Therapies, MOA, ROA, Companies by DelveInsight | Quantum Genomics, CinCor Pharma, Mineralys Therapeutics, Alnylam Therapeutics, Novartis - The Globe and Mail
Mineralys Therapeutics CEO sells $206,433 in stock - Investing.com
Mineralys Therapeutics CEO sells $206,433 in stock By Investing.com - Investing.com Canada
Mineralys therapeutics CFO Adam Levy sells $146,003 in stock By Investing.com - Investing.com South Africa
Mineralys therapeutics CFO Adam Levy sells $146,003 in stock - Investing.com
Mineralys Therapeutics Inc (MLYS) CEO Jon Congleton Sells 15,271 Shares - GuruFocus.com
Insider Sale: CFO Adam Levy Sells Shares of Mineralys Therapeuti - GuruFocus.com
Adam Scott Levy Sells 10,757 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Stock - MarketBeat
(MLYS) Trading Report - Stock Traders Daily
Mineralys Therapeutics to Unveil First Quarter Financial Results - MSN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mineralys Therapeutics, Inc.MLYS - cnhinews.com
When (MLYS) Moves Investors should Listen - Stock Traders Daily
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Shares Bought by Nantahala Capital Management LLC - MarketBeat
Driehaus Capital Management LLC Increases Holdings in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - MarketBeat
Mineralys Therapeutics Hits Enrollment Milestone in Hypertension Drug Trial - MSN
Mineralys Therapeutics to Speak at Wells Fargo Healthcare Conference - MSN
Blue Owl Capital Holdings LP Has $5.27 Million Stock Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - MarketBeat
MLYSMineralys Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Mineralys Therapeutics Hits Enrollment Milestone in Hypertension Trial - TipRanks
Mineralys Therapeutics completes target enrollment for Advance-HTN Trial - TipRanks
Mineralys Therapeutics, Inc. Completes Target Enrollment in Pivotal Advance-Htn Trial of Lorundrostat for the Treatment of Hypertension - Marketscreener.com
Mineralys Therapeutics Completes Target Enrollment in - GlobeNewswire
Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of Hypertension - StockTitan
Goldman starts Mineralys at buy, cites upcoming drug data - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Mineralys Therapeutics, Inc. (MLYS) and Encourages Shareholders to Learn More About the Investigation - AccessWire
American Century Companies Inc. Buys 23,170 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - Defense World
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Shares Sold by Adams Street Partners LLC - Defense World
Mineralys Therapeutics, Inc. (MLYS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - AccessWire
MLYS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC - GlobeNewswire
MLYS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Mineralys Therapeutics, Inc. and Encourages Investors to Contact the Firm! - Kilgore News Herald
Mineralys Therapeutics (NASDAQ:MLYS) Shares Gap Up to $11.69 - Defense World
(MLYS) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Is Investigating Mineralys Therapeutics, Inc. (MLYS) And Encourages Shareholders to Connect - AccessWire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Mineralys Therapeutics, Inc. (MLYS) and Encourages Investors to Learn More About the Investigation - AccessWire
Mineralys In Hypertension: Upcoming Catalysts And Strong Positioning (NASDAQ:MLYS) - Seeking Alpha
Mineralys Therapeutics, Inc. (MLYS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
MLYS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Mineralys Therapeutics, Inc. and Encourages Investors to Contact the Firm! - GlobeNewswire Inc.
5.11%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):